“Immunotherapy for Cancer; Current status, toxicity awareness and management”
Bruce Brockstein, MD
Head, Division of Hematology/Oncology
Kellogg Scanlon Chair in Oncology, NorthShore University HealthSystem
Clinical Professor, University of Chicago Pritzker School of Medicine
Thomas Hensing, MD
Division of Oncology, NorthShore University HealthSytem
Clinical Associate Professor, University of Chicago Pritzker School of Medicine
Laura Schmidt, PharmD
Oncology Pharmacy, NorthShore University HealthSystem
Learning Objectives:
Bruce Brockstein, MD
- List the spectrum of toxicities with checkpoint Inhibitor Immunotherapy
- Develop comfort with the management of immunotherapy toxicities
- Verbalize how development of toxicity negatively or positively affects outcomes
Thomas Hensing, MD
- Articulate the mechanism of action for this novel class of cancer therapies
- Improve capabilities for early diagnosis of immune related adverse events that are common with this class of agents
Laura Schmidt, PharmD
- List the immune checkpoint inhibitors currently in use in oncology.
- Discuss management strategies for immune checkpoint inhibitor related toxicity
Session date:
07/07/2017 - 8:00am to 9:00am CDT
Location:
NorthShore - Evanston
Evanston, IL
60201
United States
See map: Google Maps
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Speaker Name:
Bruce Brockstein, MD, Thomas Hensing, MD, and Laura Schmidt, Pharm